Human Microbiome Global Market by Disease & Data Validation, Analysis and Forecasts to 2022

image
(EMAILWIRE.COM, December 13, 2017 ) According to Publisher, the Global Human Microbiome Market is accounted for $130.23 million in 2015 and is expected to reach $521.23 million by 2022 growing at a CAGR of 21.9% during the forecast period. Increasing incidence of lifestyle diseases, growing geriatric population, and technological developments are some of the factors fueling the market growth. By product, Probiotics segment dominated the global market with largest share during the forecast period. North America and Europe commanded the market owing to the improved biotechnological and microbiological research infrastructure. However, Asia-Pacific is anticipated to grow at the highest CAGR owing to recuperating research infrastructure in the region.

For more information http://www.reportsweb.com/human-microbiome-global-market-outlook-2016-2022

Some of the key players in Human Microbiome market include Ritter Pharmaceuticals, Inc., E. I. du Pont de Nemours and Company, ViThera Pharmaceuticals, Metabiomics Corp., ActoGeniX, Optibiotix Health Plc, Vedanta Biosciences, Inc., MicroBiome Therapeutics, LLC, Second Genome, Inc., ENTEROME Bioscience, Yakult Honsha Co., Ltd., Osel, Inc., AvidBiotics, Rebiotix Inc., Merck & Co., Inc. and Seres Therapeutics.

Applications Covered:
- Diagnostics
- Therapeutics

Diseases Covered:
- Cancer
- Acute Diarrhea
- Diabetes
- Mental Disorders
- Autoimmune Disorders
- Obesity
- Other Diseases

Products Covered:
- Foods
- Drugs
- Probiotics
- Diagnostic Devices
- Prebiotics
- Medical Foods
o Nutritionally Incomplete Formulae
o Formulae for Metabolic Disorders
o Nutritionally Complete Formulae
o Oral Rehydration Products
- Other Probiotics Supplements

Request Sample Copy http://www.reportsweb.com/inquiry&RW0001564976/sample

Regions Covered:
- North America
o US
o Canada
o Mexico
- Europe
o Germany
o France
o Italy
o UK
o Spain
o Rest of Europe
- Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o Rest of Asia Pacific
- Rest of the World
o Middle East
o Brazil
o Argentina
o South Africa
o Egypt

10 Company Profiling
10.1 Ritter Pharmaceuticals, Inc.
10.2 E. I. du Pont de Nemours and Company
10.3 ViThera Pharmaceuticals
10.4 Metabiomics Corp.
10.5 ActoGeniX
10.6 Optibiotix Health Plc
10.7 Vedanta Biosciences, Inc.
10.8 MicroBiome Therapeutics, LLC
10.9 Second Genome, Inc.
10.10 ENTEROME Bioscience
10.11 Yakult Honsha Co., Ltd.
10.12 Osel, Inc.
10.13 AvidBiotics
10.14 Rebiotix Inc.,
10.15 Merck & Co., Inc.
10.16 Seres Therapeutics

Make an enquiry: http://www.reportsweb.com/inquiry&RW0001564976/buying

Source : http://www.emailwire.com/release/555721-Human-Microbiome-Global-Market-by-Disease-Data-Validation-Analysis-and-Forecasts-to-2022.html

Related Posts